Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for KRAS wild-type pancreatic ductal adenocarcinoma, drawn from the whole corpus: 3 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Fusion testing is still missed when DNA panels are used alone, so many actionable tumours go unrecognised.
Each driver is too rare for pancreatic-specific randomised trials; evidence is extrapolated from lung cancer and basket studies.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Resistance to fusion-targeted drugs follows lung cancer patterns and second-line options are thin.
Nothing recorded yet.
Nothing recorded yet.
Background: Drug resistance (primary and acquired). Also on OnCo: Resistance atlas · Lines of therapy.
Some KRAS wild-type cases are misclassified periampullary cancers, which confounds every series.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 8 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Overall survival improved with nimotuzumab plus gemcitabine in KRAS wild-type disease.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.